NAT2

gene product
AAC2
This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq, Jul 2008]
More gene data

Featured antibodies

Antibodies

 

Filters

Application

Antibodypedia Validation Initiative

Validation method

Reference

Provider

Host

Reactivity

Antibody type

Conjugate

Antibody

  or   Clear
Enhanced validation
Enhanced validation
Supportive data in Antibodypedia
Data presented on provider website
Data in Antibodypedia (inconclusive)
Validated within AVI
Eligible for validation within AVI
253 antibodies from 25 providers.

Antibody properties

General

Applications

or Cancel
Antibody
antibodies-online
127 antibodies
Biorbyt
18 antibodies
Aviva Systems Biology
5 antibodies
Abgent
3 antibodies
Invitrogen Antibodies
4 antibodies
LifeSpan BioSciences, Inc.
33 antibodies
ProSci
3 antibodies
Novus Biologicals
7 antibodies
OriGene
5 antibodies
Abnova Corporation
5 antibodies
GeneTex
2 antibodies
St John's Laboratory
2 antibodies
RabMAbs
1 antibody
Signalway Antibody LLC
1 antibody
MyBioSource
4 antibodies
Acris Antibodies GmbH
2 antibodies
Creative Diagnostics
2 antibodies
Abbexa
6 antibodies
Boster Biological Technology
1 antibody
NovoPro Bioscience Inc.
1 antibody
United States Biological
13 antibodies
Creative Biolabs
3 antibodies
Leading Biology
2 antibodies
Sigma-Aldrich
2 antibodies
Everest Biotech
1 antibody